TABLE 3.
Synergistic inhibition by LP-40 and LP-11 of diverse HIV-1 isolatesa
| Virus | Subtype | CI | LP-40 inhibition (IC50 [nM]) |
Dose reduction (n-fold) | LP-11 inhibition (IC50 [nM]) |
Dose reduction (n-fold) | ||
|---|---|---|---|---|---|---|---|---|
| Alone | In mixture | Alone | In mixture | |||||
| 92UG037.8 | A | 0.37 | 2.36 | 0.52 | 4.54 | 0.85 | 0.13 | 6.54 |
| NL4-3D36G | B | 0.49 | 0.89 | 0.25 | 3.56 | 0.37 | 0.08 | 4.63 |
| JRCSF | B | 0.31 | 5.69 | 0.22 | 25.86 | 0.82 | 0.22 | 3.73 |
| R3A | B | 0.39 | 0.44 | 0.11 | 4.00 | 0.77 | 0.11 | 7.00 |
| AC10.0.29 | B | 0.28 | 1.62 | 0.24 | 6.75 | 0.46 | 0.06 | 7.67 |
| TRO.11 | B | 0.50 | 4.93 | 1.08 | 4.56 | 0.95 | 0.27 | 3.52 |
| JRFL | B | 0.27 | 1.76 | 0.22 | 8.00 | 3.10 | 0.44 | 7.05 |
| SF162 | B | 0.55 | 3.97 | 1.15 | 3.45 | 1.87 | 0.58 | 3.22 |
| B02 | B' | 0.42 | 0.93 | 0.25 | 3.72 | 1.66 | 0.25 | 6.64 |
| CE1176_A3 | C | 0.64 | 1.32 | 0.64 | 2.06 | 1.04 | 0.16 | 6.50 |
| X1632-S2-B10 | G | 0.48 | 2.50 | 0.70 | 3.57 | 0.86 | 0.17 | 5.06 |
| AE03 | A/E | 0.46 | 3.29 | 0.71 | 4.63 | 0.75 | 0.18 | 4.17 |
| CNE8 | A/E | 0.51 | 4.51 | 1.25 | 3.61 | 1.37 | 0.32 | 4.28 |
| CNE55 | A/E | 0.77 | 3.46 | 1.03 | 3.36 | 0.55 | 0.26 | 2.12 |
| CH64.20 | B/C | 0.52 | 4.14 | 1.09 | 3.78 | 0.43 | 0.11 | 3.91 |
| CH119.10 | B/C | 0.55 | 2.22 | 0.69 | 3.22 | 0.72 | 0.17 | 4.24 |
| Mean | 0.47 | 2.75 | 0.63 | 5.54 | 1.04 | 0.22 | 5.02 | |
a
The assay was performed in triplicate and repeated 3 times, and representative data are shown.